Cardioplegic (Baxter Healthcare Corporation)
Welcome to the PulseAid listing for the Cardioplegic drug offered from Baxter Healthcare Corporation. This Blood Coagulation Factor [EPC],Increased Coagulation Factor Activity [PE],Calcium [Chemical/Ingredient],Cations, Divalent [Chemical/Ingredient],Calculi Dissolution Agent [EPC],Magnesium Ion Exchange Activity [MoA],Osmotic Laxative [EPC],Osmotic Activity [MoA],Inhibition Small Intestine Fluid/Electrolyte Absorption [PE],Increased Large Intestinal Motility [PE],Stimulation Large Intestine Fluid/Electrolyte Secretion [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Potassium Compounds [Chemical/Ingredient],Potassium Salt [EPC],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Baxter Healthcare Corporation |
| NON-PROPRIETARY NAME: | Calcium Chloride, Magnesium Chloride, Potassium Chloride and Sodium Chloride |
| SUBSTANCE NAME: | CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Blood Coagulation Factor [EPC],Increased Coagulation Factor Activity [PE],Calcium [Chemical/Ingredient],Cations, Divalent [Chemical/Ingredient],Calculi Dissolution Agent [EPC],Magnesium Ion Exchange Activity [MoA],Osmotic Laxative [EPC],Osmotic Activity [MoA],Inhibition Small Intestine Fluid/Electrolyte Absorption [PE],Increased Large Intestinal Motility [PE],Stimulation Large Intestine Fluid/Electrolyte Secretion [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Potassium Compounds [Chemical/Ingredient],Potassium Salt [EPC],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA] |
| ROUTE: | INTRA-ARTERIAL |
| DOSAGE FORM: | SOLUTION |
| MARKETING CATEGORY NAME: | ANDA |
| START MARKETING DATE: | 2000-04-21 |
| END MARKETING DATE: | 0000-00-00 |
Cardioplegic HUMAN PRESCRIPTION DRUG Details:
| Item Description | Cardioplegic from Baxter Healthcare Corporation |
| LABELER NAME: | Baxter Healthcare Corporation |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 17.6; 325.3; 119.3; 643(mg/100mL; mg/100mL; mg/100mL; mg/100mL) |
| START MARKETING DATE: | 2000-04-21 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0338-0341_32d27009-8568-4468-b8cc-7be67d27d783 |
| PRODUCT NDC: | 0338-0341 |
| APPLICATION NUMBER: | ANDA075323 |
Other CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE Pharmaceutical Manufacturers / Labelers:
